Skip to main content
Premium Trial:

Request an Annual Quote

Hood Wins $400K Kyoto Prize; Karanewsky To Head Deltagen Research Labs; and others

NEW YORK, June 26 - Structural Bioinformatics said on Monday said Ruth Nutt will be the company's new acting head of drug discovery as well as a member of its Scientific Advisory Board.

 

She will oversee all drug discovery efforts and report to the company president.

 

Nutt is joining the company from Corvas International, where she directed the medicinal and analytical chemistry discovery research efforts. Prior to that, she spent 31 years at Merck. Nutt holds more than 30 patents.

 

Structural Bioinformatics is based in San Diego, Calif.

 


 

 

Hyseq Pharmaceuticals yesterday said it had chosen Nina Giles to become its vice president of business development.

 

Giles was with Incyte from 1997 to 2002. Most recently, she was the company's vice president of business development, where she was involved in licensing, collaborations, and alliances.

 


 

 

The 2002 Kyoto Prize for Advanced Technology will be awarded to Leroy Hood, president and director of the Institute for Systems Biology, the Japanese  Inamori Foundation said on June 21.

 

The award, which will be given on November 10 in Kyoto, includes a gold medal, a diploma, and 50 million yen (about $400,000).

 

Hood is being recognized for his work mapping the human genome.

 

The Kyoto Prizes are given each year to people who are said to have "contributed significantly to human progress" in the areas of Advanced Technology, Basic Sciences, and Arts and Philosophy".

 

The Inamori foundation, founded by Kyocera chairman emeritus Kazuo Inamori in 1984, has assets of 64.5 billion yen (about $500 million US).

 


 

 

Iconix Pharmaceuticals said on June 20 it had appointed Roy Whitfield, the chair of Incyte Genomics, to its board of directors.

 

Iconix will rely on Whitfield's business expertise as it commercializes its chemogenomics research. The company is based in Mountain View, Calif.

 


 

Deltagen chose Donald Karanewsky to become its senior vice president and the new site director of Deltagen Research Laboratories, the company said on June 20.

 

He replaces Peter Myers, who resigned earlier this month.

 

Karanewsky was previously vice president of medical chemistry and deputy director of research at Ligand Pharmaceuticals, where he directed late-stage drug discovery.

 


 

 

Promoted? Changing jobs? GenomeWeb wants to know. E-mail Kathleen McGowan at [email protected] to appear in PEOPLE, a roundup of personnel comings and goings in genomics, that appears every Wednesday.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.